Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment ...

The study confirmed that ritlecitinib was well tolerated among participants, making it a potential candidate for systemic therapy in alopecia areata[2]. In addition to these specific treatments ...

The risk for alopecia areata is increased among patients with lower serum levels of vitamin D and zinc, but no relationship was observed with copper.

The global alopecia treatment market size was valued at USD 3.48 billion in 2024 and is projected to reach from USD 3.62 billion in 2025 to USD 5.20 billion by 2033, growing at a CAGR of 4.1% during ...

Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles. Breakdown of immune privilege in hair follicles leads to ...

Superficial cryotherapy is a novel cold-based treatment that has emerged as a potential therapy for patchy alopecia areata ...

Please provide your email address to receive an email when new articles are posted on . Alopecia areata was classified as early-onset, severe or prolonged. Each additional atopic comorbidity ...

An autoimmune condition known as alopecia areata affects the hair follicles, leading to hair loss, breakage, and complete baldness. Hormonal changes, genetic disorders, head radiation therapy ...

Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition that affects around ...